Budd-Chiari Syndrome
Budd-Chiari syndrome is a rare condition in which blood flow out of the liver is obstructed at the level of the hepatic veins or the inferior vena cava just above the liver. Most cases result from blood clots, often in the setting of an inherited or acquired clotting disorder, although tumor invasion, infection, and other less common causes are also recognized. Budd-Chiari syndrome can present acutely with abdominal pain, ascites, and liver dysfunction or develop more gradually with signs of chronic liver disease and portal hypertension. Imaging—particularly Doppler ultrasound, CT, and MRI venography—is central to diagnosis, and treatment is highly individualized.
What is it?
Blood that flows into the liver from the portal vein and hepatic artery normally leaves the liver through the hepatic veins, which drain into the inferior vena cava (IVC) and then into the heart. Budd-Chiari syndrome is a condition in which this hepatic venous outflow is obstructed at the level of the hepatic veins, the junction where they enter the IVC, or the IVC just above the liver. When outflow is impaired, blood backs up within the liver, causing congestion, swelling, impaired function, and—over time—structural changes that can resemble those seen in other forms of chronic liver disease. Conditions in which the obstruction is at the level of the small veins within the liver are usually classified separately as sinusoidal obstruction syndrome (formerly called veno-occlusive disease) and are not part of Budd-Chiari syndrome.
Budd-Chiari syndrome can develop suddenly (acute or fulminant), over weeks to months (subacute), or slowly over years (chronic). Acute or fulminant forms can present with severe abdominal pain, rapidly accumulating ascites, jaundice, and—in the most severe cases—acute liver failure with confusion, coagulopathy, and multi-organ involvement. More commonly, Budd-Chiari syndrome develops gradually, with progressive signs of portal hypertension (such as ascites, varices, splenomegaly), liver enlargement, and chronic liver dysfunction.
The most common cause of Budd-Chiari syndrome in many regions is blood clots in the hepatic veins or IVC, often related to an underlying clotting disorder. Myeloproliferative neoplasms—particularly those with the JAK2 V617F mutation (such as polycythemia vera, essential thrombocythemia, and primary myelofibrosis)—are among the most frequent identified contributors. Other recognized causes include antiphospholipid syndrome, paroxysmal nocturnal hemoglobinuria, inherited thrombophilias (such as factor V Leiden, prothrombin gene mutation, and protein C, S, or antithrombin deficiency), pregnancy and the postpartum period, oral contraceptive use, certain infections, abdominal inflammation, malignancy with tumor invasion of the hepatic veins or IVC (such as hepatocellular carcinoma and renal cell carcinoma), and prior abdominal surgery or trauma. In certain regions, membranous obstruction of the IVC is a relatively more common cause, often in younger patients. Several factors frequently coexist, and identifying all contributing causes is important because patients often have more than one risk factor.
Symptoms vary widely depending on how quickly the obstruction develops, how extensive it is, and how well the liver can adapt through small collateral veins that may form. Common features include upper right abdominal pain, abdominal swelling from ascites, leg swelling, enlarged liver, nausea, fatigue, and weight changes. Jaundice may develop, particularly in more severe forms. Patients with chronic disease may present with signs of portal hypertension such as variceal bleeding, splenomegaly, and low platelet counts. Severe acute forms can present with rapid clinical deterioration, including signs of acute liver failure. A subset of patients are diagnosed incidentally when imaging shows characteristic hepatic vein or IVC findings during evaluation for other conditions.
Diagnosis combines clinical assessment with imaging and laboratory testing. Doppler ultrasound of the liver, hepatic veins, and IVC is often the first imaging study and can show hepatic vein thrombosis, abnormal flow patterns, intrahepatic collateral veins, and signs of liver congestion. CT and MRI with venography provide detailed three-dimensional information about the hepatic veins, IVC, and liver parenchyma; characteristic findings include hepatic vein occlusion or narrowing, enlargement of the caudate lobe (which has separate drainage), patchy contrast enhancement reflecting altered blood flow, and signs of portal hypertension. Catheter-based venography may be used in selected patients, often at the time of planned intervention, and allows direct measurement of pressures across narrowed segments. Liver biopsy may be helpful in select cases, particularly when the diagnosis is unclear or when the extent of liver injury needs to be assessed.
Investigation of underlying causes is an essential part of the evaluation. Blood tests typically include a complete blood count, liver function tests, INR, kidney function, and a comprehensive thrombophilia panel (including testing for myeloproliferative neoplasms and the JAK2 V617F mutation, antiphospholipid antibodies, paroxysmal nocturnal hemoglobinuria, and inherited thrombophilias). Pregnancy testing, hormonal therapy history, and evaluation for malignancy and inflammatory conditions are also important.
Important to Know
Management of Budd-Chiari syndrome is highly individualized and depends on the severity of disease, how quickly it has developed, the underlying cause, and the patient’s overall health. Because the condition is rare and complex, care is best delivered in centers with expertise in liver disease, vascular interventions, hematology, and transplantation. A typical multidisciplinary team may include hepatologists, hematologists, interventional radiologists, hepatobiliary surgeons, transplant specialists, oncologists (when malignancy is involved), and others.
Anticoagulation is recommended for most patients with Budd-Chiari syndrome, including many of those with non-thrombotic causes, to prevent further clot formation and reduce the risk of progression. The specific anticoagulant (such as direct oral anticoagulants, low-molecular-weight heparin, or warfarin) is selected based on liver function, kidney function, bleeding risk, the underlying clotting disorder, and other patient factors. Duration is often long-term or lifelong, particularly in the setting of inherited or persistent clotting disorders.
Treatment of the underlying cause is essential. Myeloproliferative neoplasms are managed in collaboration with hematology, including specific therapies such as cytoreductive medications and—in selected patients—JAK inhibitors. Antiphospholipid syndrome, paroxysmal nocturnal hemoglobinuria, and other clotting disorders have their own specific treatments. Tumor-related Budd-Chiari syndrome requires coordination with oncology. Pregnancy- and contraception-related risks are individualized in collaboration with obstetrics.
Medical management of complications of portal hypertension follows similar principles as for cirrhosis and includes nonselective beta-blockers and endoscopic banding for varices, diuretics and sodium restriction for ascites, antibiotic prophylaxis for spontaneous bacterial peritonitis in selected patients, and lactulose and rifaximin for hepatic encephalopathy.
Catheter-based interventions play a central role in many patients with Budd-Chiari syndrome. Balloon angioplasty and stenting of focal narrowings or membranous obstructions of the hepatic veins or IVC can dramatically restore flow in appropriately selected patients. Transjugular intrahepatic portosystemic shunt (TIPS) creates a new channel between the portal and hepatic veins inside the liver, reducing portal pressure and improving liver outflow when direct hepatic vein interventions are not feasible. TIPS has become a key treatment in many patients with refractory ascites, recurrent variceal bleeding, or progressive disease despite anticoagulation. Surgical shunts are used less commonly today.
Liver transplantation is considered in patients with fulminant Budd-Chiari syndrome, advanced chronic disease that is not controlled with other measures, severe complications, or unresectable hepatocellular carcinoma in eligible patients. Transplantation can provide long-term recovery, although ongoing management of the underlying clotting disorder and its risks remains essential after transplant.
Surveillance for hepatocellular carcinoma, monitoring for complications of portal hypertension and liver dysfunction, vaccination (such as for hepatitis A and B, influenza, pneumococcal infection, and COVID-19), nutritional support, and treatment of associated conditions all play important roles. Patient education—including understanding the long-term need for anticoagulation, the importance of follow-up, recognizing warning signs of bleeding or worsening liver disease, and the impact of pregnancy and hormonal therapy—is an important component of care.
Family screening may be appropriate for patients with inherited clotting disorders, particularly when there is a strong family history of clotting events.
Red flag symptoms include severe upper abdominal pain, rapidly progressive abdominal swelling with shortness of breath or fever, severe jaundice, vomiting blood or coffee-ground material, black or tarry stools, signs of severe infection, confusion or sleep changes, severe lethargy or difficulty arousing, severe leg swelling with shortness of breath, or signs of shock. These warrant immediate emergency evaluation, as they may indicate acute liver failure, variceal bleeding, severe infection, or other serious complications.